Registered number: SC154034

Almac Sciences (Scotland) Limited
Annual report and financial statements
for the year ended 30 September 2021





Annual report and financial statements for the year ended 30 September 2021

Contents

					٠.	Page(s)
Directors and advisers						1
Directors' report				. •		2 - 3
Statement of directors' responsibilit	ies in respect o	f the financ	ial staten	nents		. 4
Independent auditors' report to the r	nembers of Alr	nac Science	s (Scotla	and) Limited		5 - 7
Income statement		•				8
Statement of changes in equity						9
Balance sheet	. ·		•			10
Cash flow statement			•			11
Notes to the financial statements	,					12 - 38

Directors and advisers

Directors

A D Armstrong

S. A Barr

C Hayburn

S Campbell

N Harkin

Company secretary

C Hayburn

Registered office

5 Fleming Building Edinburgh Technopole Milton Bridge Penicuik EH26 0BE

Solicitors

Dundas and Wilson Saltire Court 20 Castle Terrace Edinburgh EH1 2EN

Bankers

Danske Bank
11 Donegall Square West
Belfast
BT1 6JS

Independent auditors

PricewaterhouseCoopers LLP Chartered Accountants and Statutory Auditors Merchant Square 20-22 Wellington Place Belfast BT1 6GE

Directors' report for the year ended 30 September 2021

The directors present their annual report and the audited financial statements of the company for the year ended 30 September 2021.

Principal activities

Almac Sciences (Scotland) Limited is a private limited company incorporated and domiciled in the United Kingdom and registered in Scotland. The company's registered address is detailed on page 1.

The principal activity of the company is the provision of custom chemical synthesis services.

Financial risk management

The company operates within the competitive conditions of its marketplace. Regarding credit risk, it is standard company policy to perform appropriate credit checks on all potential customers before contracts are entered into. Further commentary is provided in note 2.

Results and dividends

The profit for the financial year attributable to owners of the company is £745,340 (2020: £2,440,904). The directors do not recommend payment of a dividend (2020: £nil).

Directors

The directors who served during the year and up to the date of approval of the financial statements are listed below:

A D Armstrong

S A Barr

C Hayburn

S Campbell

N Harkin

Directors' indemnities

The directors have the benefit of an indemnity, which is a qualifying third party indemnity provision as defined by Section 234 of the Companies Act 2006. The indemnity was in force throughout the last financial year and is currently in force.

Going concern

The directors of Almac Group Limited have prepared cash flow forecasts for a period of at least twelve months from the date of signing of this report and confirm that adequate funding has been committed by Almac Group Limited, the company's ultimate parent, to support the company's operations and planned growth over this period. The directors have received confirmation that Almac Group Limited intends to support the company for at least one year after these financial statements are signed. Consequently, the directors have prepared these financial statements on a going concern basis.

The Company participates in group cash pooling arrangements providing access to cash necessary for the day-to-day running of the company and to support the going concern assertion. The company has received confirmation that the Group will not withdraw the facility in the foreseeable future.

After making enquiries, the directors have a reasonable expectation that the company has access to adequate financial and other resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Covid 19

The Covid 19 pandemic has brought disruption to the operations of many businesses including the company. As a company servicing the global pharmaceutical and biotech sectors it has also presented some commercial opportunities. It has led to an unprecedented level of market volatility and economic uncertainty. These events and conditions have been considered in the preparation of these financial statements, where management has exercised its judgement in the process of applying the company's accounting policies. There are no areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements.

Directors' report for the year ended 30 September 2021 (continued)

Covid 19 (continued)

The carrying amounts of the Company's non-financial and financial assets have been assessed to determine whether there is any objective evidence or indication that these assets may be impaired, taking into consideration the conditions existing at the balance sheet date including the impact of the Covid 19 pandemic. There is no material adverse financial impact arising from the assessments carried out by the management.

As the global Covid 19 situation remains fluid at the date these financial statements were authorized for issue, the company cannot reasonably ascertain the full extent of the probable impact of the Covid 19 disruptions on its operating and financial performance for the financial year ending 30 September 2022.

Research and development

The company is committed to research and development in the area of drug discovery on behalf of third parties. Research carried out in the year was expensed as incurred. No development expenditure was incurred in the year (2020: £nil).

Employees

The company systematically provides employees with all information on matters of concern to them, consulting them or their representatives regularly, so that their views can be taken into account when making decisions that are likely to affect their interests. Employee involvement in the company is encouraged, as achieving a common awareness on the part of all employees of the financial and economic factors affecting the company plays a major role in objectives.

The company is committed to employment policies, which follow best practice based on equal opportunities for all employees, irrespective of sex, race, colour, disability or marital status. The company gives full and fair considerations to applications for employment from disabled persons, having regard to their particular aptitudes and abilities. Appropriate arrangements are made for the continued employment and training, career development and promotion of disabled persons employed by the company. If members of staff become disabled the company continues employment, either in the same or an alternative position with appropriate retraining being given if necessary.

Statement of disclosure of information to auditors

So far as each of the directors in office at the date of approval of these financial statements is aware:

- there is no relevant audit information of which the company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Independent auditors

The independent auditors, PricewaterhouseCoopers LLP, have indicated their willingness to continue in office, and a resolution concerning their re-appointment will be proposed at the Annual General Meeting.

Small companies' exemption

The above report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006. The company has also availed of the small companies exemption in respect of the preparation of a Strategic Report.

This report was approved by the board and signed on its behalf.

N Harkin **Director**

20 January 2022

Statement of directors' responsibilities in respect of the financial statements

The directors are responsible for preparing the Annual report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with UK-adopted international accounting standards.

Under company law, directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable UK-adopted international accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are also responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.

N Harkin **Director**

20 January 2022

Independent auditors' report to the members of Almac Sciences (Scotland) Limited

Report on the audit of the financial statements

Opinion

In our opinion, Almac Sciences (Scotland) Limited's financial statements:

- give a true and fair view of the state of the company's affairs as at 30 September 2021 and of its profit and cash flows for the year then ended:
- have been properly prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual report and financial statements (the "Annual Report"), which comprise: the balance sheet as at 30 September 2021; the income statement, the cash flow statement, the statement of changes in equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

Independent auditors' report to the members of Almac Sciences (Scotland) Limited (continued)

Reporting on other information (continued)

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Directors' report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Directors' report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Directors' report for the year ended 30 September 2021 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Directors' report.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Statement of directors' responsibilities in respect of the financial statements, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the company and industry, we identified that the principal risks of non-compliance with laws and regulations related to product safety (including but not limited to Medicines and Healthcare products Regulatory Agency regulations) and tax legislation, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to manipulate financial results, including revenue recognition and manipulation of earnings before interest, tax, depreciation and amortisation and management bias in accounting estimates or significant judgements. Audit procedures performed by the engagement team included:

Independent auditors' report to the members of Almac Sciences (Scotland) Limited (continued)

Responsibilities for the financial statements and the audit (continued)

Auditors' responsibilities for the audit of the financial statements (continued)

- Discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulation and fraud:
- · Identifying and testing unusual journal entries, in particular those journal entries posted with an unusual account combination; and
- Evaluating and, where appropriate, challenging assumptions and judgements made by management in determining significant accounting estimates.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Entitlement to exemptions

Under the Companies Act 2006 we are required to report to you if, in our opinion, the directors were not entitled to: take advantage of the small companies exemption in preparing the Directors' report; and take advantage of the small companies exemption from preparing a strategic report. We have no exceptions to report arising from this responsibility.

Brenda Heenan (Senior Statutory Auditor)

for and on behalf of PricewaterhouseCoopers LLP

Chartered Accountants and Statutory Auditors

Belfast

1 February 2022

Income statement for the year ended 30 September 2021

		2021	2020
	Note	£	£
Continuing operations			
Revenue	4	4,843,606	6,299,143
Cost of sales	. 6	(3,063,865)	(2,854,536)
Gross profit		1,779,741	3,444,607
Administrative expenses	6	(946,255)	(586,185)
Operating profit		833,486	2,858,422
Operating profit as analysed as:			· · ·
Operating profit before depreciation and amortisation		1,575,766	3,505,318
Depreciation of property, plant and equipment		(497,831)	(440,627)
Depreciation of right of use asset	•	(200,974)	(196,936)
Amortisation of intangible assets		(43,475)	.(9,333)
Finance income	5	25,590	50,100
Finance costs	5 ,	(58,724)	(62,156)
Profit before income tax		800,352	2,846,366
Income tax charge	8	(55,012)	(405,462)
Profit for the financial year		745,340	2,440,904

The notes on pages 12 to 38 are an integral part of these financial statements.

There is no other comprehensive income for the year (2020: £nil).

Statement of changes in equity for the year ended 30 September 2021

	Share capital £	Share premium account £	(Accumulated losses)/Retained earnings	Total equity £
At 1 October 2019	1,036,025	908,869	(2,506,467)	(561,573)
Profit for the financial year		· · · · · · · · · · · · · · · · · · ·	2,440,904	2,440,904
Arising on adoption of IFRS 16	-		(99,945)	(99,945)
At 30 September 2020 and 1 October 2020	1,036,025	908,869	(165,508)	1,779,386
Profit for the financial year	· -·		745,340	745,340
At 30 September 2021	1,036,025	908,869	579,832	. 2,524,726

The notes on pages 12 to 38 are an integral part of these financial statements.

Balance sheet as at 30 September 2021

		2021	2020
	Note	£	£
Assets			
Non-current assets			
Intangible assets	9	25,952	69,427
Property, plant and equipment	10	3,578,512	3,498,065
Right-of-use-assets	-11	1,650,214	1,828,452
Deferred tax asset	12	391,306	455,210
Total non-current assets		5,645,984	5,851,154
Current assets			
Trade and other receivables	13	3,798,492	2,491,686
Total current assets		3,798,492	2,491,686
Total assets		9,444,476	8,342,840
Liabilities			
Current liabilities			
Borrowings	14	3,556,261	3,530,102
Trade and other payables	15	863,907	696,346
Total current liabilities		4,420,168	4,226,448
Non-current liabilities			
Borrowings	14	1,589,617	1,775,598
Other non-current liabilities	16	87,790	97,617
Deferred income	17	822,175	463,791
Total non-current liabilities		2,499,582	2,337,006
Total liabilities		6,919,750	6,563,454
Equity attributable to owners of the company			
Share capital	18	1,036,025	1,036,025
Share premium account		908,869	908,869
Retained earnings/(Accumulated losses)		579,832	(165,508)
Total equity		2,524,726	1,779,386
Total equity and liabilities		9,444,476	8,342,840

The notes on pages 12 to 38 are an integral part of these financial statements.

The financial statements on pages 8 to 38 were authorised for issue by the board of directors on 20 January 2022 and were signed on their behalf by:

A D Armstrong

Director

Almac Sciences (Scotland) Limited

S Campbell **Director**

Registered number: SC154034

Cash flow statement for the year ended 30 September 2021

	•				2021	2020
			Note	٠.	£	£
Cash flows from operating activities			:			
Cash generated from operations			19		867,026	737,920
Interest paid	. '	•			. (273)	(129)
Taxation recovered	÷.				294,350	257,545
Net cash generated from operating activities	<u> </u>		:	····	1,161,103	995,336
Cash flows from investing activities						e.
Purchase of property, plant and equipment			•		(578,278)	(888,082)
Interest received			•		25,590	50,100
Purchase of intangible assets				• .	-	(74,217)
Net cash used in investing activities ·				· ·	(552,688)	(912,199)
Cash flows from financing activities		·				
Net advances to group undertakings	•	•			(800,673)	146,696
Principal elements of lease payments					(241,008)	(229,833)
Capital grants received			. •		433,266	· -
Net cash used in financing activities				. :	(608,415)	(83,137)
Net decrease in cash and cash equivalents			-			-
Cash and cash equivalents at beginning of the year			•	•	<i>;</i>	-
Cash and cash equivalents at end of the year					. •	-

The notes on pages 12 to 38 are an integral part of these financial statements.

Notes to the financial statements for the year ended 30 September 2021

1 Accounting policies

General information.

The company's principal activity during the year was as described in the directors' report. The financial statements are presented in UK pound sterling. Almac Sciences (Scotland) Limited is a private limited company incorporated by shares and domiciled in the United Kingdom and registered in Scotland. The company's registered address is detailed on page 1.

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation

The financial statements of Almac Sciences (Scotland) Limited have been prepared on the going concern basis and in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 as applicable to companies using IFRS. The financial statements have been prepared under the historical cost convention.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the company's accounting policies. Management has concluded that there are no critical assumptions, estimates or judgements involving a high degree of judgment or complexity which require further disclosure. The company's accounting policies and estimates are detailed below.

Going concern

The directors of Almac Group Limited have prepared cash flow forecasts for a period of at least twelve months from the date of signing of this report and confirm that adequate funding has been committed by Almac Group Limited, the company's ultimate parent, to support the company's operations and planned growth over this period. The directors have received confirmation that Almac Group Limited intends to support the company for at least one year after these financial statements are signed. Consequently, the directors have prepared these financial statements on a going concern basis.

The Company participates in group cash pooling arrangements providing access to cash necessary for the day-to-day running of the company and to support the going concern assertion. The company has received confirmation that the Group will not withdraw the facility in the foreseeable future.

After making enquiries, the directors have a reasonable expectation that the company has access to adequate financial and other resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

New standards, amendments and interpretations effective in the year to 30 September 2021

The accounting policies set out below are those that the company has adopted in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 for the year ended 30 September 2021.

No standards have been adopted by the company for the first time during the financial year beginning on or after 1 October 2020 that have had a material impact on the company.

Standards, amendments, and interpretations that are not yet effective and have not been adopted early by the company

Certain new accounting standards and interpretations have been published that are not mandatory for 30 September 2021 reporting periods and have not been early adopted by the company. None of these are expected to have a material impact on the company in the current or future reporting periods and on foreseeable future transactions.

1 Accounting policies (continued)

Intangible assets

Computer software

The costs of acquiring and bringing computer software into use are capitalised and amortised on a straight-line basis over the estimated useful economic life of the software which is between three to five years.

Computer software

Capitalised software development costs include external direct costs of material and services together with direct labour costs relating to software development. Development costs that are directly attributable to the design and testing of identifiable and unique software products controlled by the company are recognised as intangible assets when the following criteria are met:

- it is technically feasible to complete the software product so that it will be available for use;
- management intends to complete the software product and use or sell it;
- there is an ability to use or sell the software product
- it can be demonstrated how the software product will generate probable future economic benefits;
- adequate technical, financial and other resources to complete the development and to use or sell the software product are available; and
- the expenditure attributable to the software product during its development can be reliably measured.

Directly attributable costs that are capitalised as part of the software product include the software development employee costs and an appropriate portion of relevant overheads. Other development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

Property, plant and equipment

Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance expenses are charged to the income statement during the financial year in which they are incurred. For all assets, depreciation is calculated so as to write off the cost less their estimated residual values, on a straight-line basis over the expected useful economic lives of the assets concerned. The principal annual rates used are as follows:

Long leasehold buildings -	10
Plant and machinery -	10-
Fixtures, fittings and equipment -	20

'No depreciation is charged on land. The assets' residual values and useful economic lives are reviewed, and adjusted if appropriate, at each balance sheet date. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains and losses on disposal are determined by comparing the proceeds with the carrying amount and are included within administrative expenses in the income statement.

Notes to the financial statements for the year ended 30 September 2021 (continued)

1 Accounting policies (continued)

Impairment of non-financial assets

At each balance sheet date non-financial assets not carried at fair value are assessed to determine whether there is an indication that the asset (or asset's cash generating unit) may be impaired. If there is such an indication, the recoverable amount of the asset (or asset's cash generating unit) is compared to the carrying amount of the asset (or asset's cash generating unit).

The recoverable amount of the asset (or asset's cash generating unit) is the higher of the fair value less costs to sell and value in use. Value in use is defined as the present value of the future cash flows before interest and tax obtainable as a result of the asset's (or asset's cash generating unit) continued use. These cash flows are discounted using a pre-tax discount rate that represents the current market risk-free rate and the risks inherent in the asset.

If the recoverable amount of the asset (or asset's cash generating unit) is estimated to be lower than the carrying amount, the carrying amount is reduced to its recoverable amount. An impairment loss is recognised in the profit and loss account, unless the asset has been revalued when the amount is recognised in other comprehensive income to the extent of any previously recognised revaluation. Thereafter, any excess is recognised in profit and loss account.

Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one party and a financial liability or equity instrument of another party. Financial assets of the company include cash and cash equivalents, trade and other receivables, and favourable derivative financial instruments. Financial liabilities of the company include trade and other payables, borrowings and unfavourable derivative financial instruments.

Initial recognition and measurement

Financial assets and liabilities are recognised in the statement of financial position when the company becomes a party to the contractual obligations of the instrument.

The company classifies its financial assets in the following measurement categories

- i) Those to be measured at amortised costs; and
- ii) Those to be measured subsequently at fair value (either through other comprehensive income of through profit or loss).

The classification depends on the company's business model for managing the financial assets and the contractual terms of the cash flows. The company reclassifies its financial assets when and only when its business model for managing those assets changes.

At initial recognition, the company measures a financial asset at its fair value plus transaction costs that are directly attributable to the acquisition of the financial asset.

Financial liabilities are classified as financial liabilities at fair value through profit or loss, other financial liabilities at amortised cost or as derivatives.

Financial liabilities are recognised at fair value plus, in the case of financial instruments not at fair value through profit and loss, transaction costs that are directly attributable to the acquisition or issue of the financial liability. Transaction costs directly attributable to financial liabilities which are measured at fair value (i.e. fair value through profit and loss or derivatives) are recognised in the income statement as incurred.

Subsequent measurement

Subsequent to recognition, financial assets and liabilities are measured according to the category to which they are classified.

(a) Financial assets

Subsequent measurement of financial assets depends on the company's business model for managing those financial assets and the cash flow characteristics of those financial assets. The company only has financial assets classified at amortised cost. These assets are those held for contractual collection of cash flows, where those cash flows represent solely payments of principal and interest and are held at amortised cost. Any gains or losses arising on derecognition is recognised directly in profit or loss.

1 Accounting policies (continued)

Financial instruments (continued)

(b) Financial liabilities at fair value through profit and loss

Financial liabilities are classified as at fair value through profit or loss when the financial liability is either held for trading or it is designated as at fair value through profit or loss.

Financial liabilities at fair value through profit or loss are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the 'other gains and losses' line item in the income statement.

(c) Other financial liabilities

Trade and other payables and borrowings (including amounts due to related parties) are classified as other financial liabilities

and are initially measured at fair value, net of transaction costs and subsequently measured at amortised cost using the effective interest rate method (see below).

Effective interest method

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income and expenses over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Income is recognised on an effective interest basis for debt instruments other than those financial assets classified as fair value through profit or loss.

Derecognition

The company derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the company retains substantially all the risks and rewards of ownership of a transferred financial asset, the company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the income statement.

Impairment of a financial asset

The company assesses on a forward-looking basis, the expected credit losses associated with its debt instruments carried at amortised cost. For trade receivables the company applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognised from the initial recognition of the receivables. For other receivables the company applies the three stage model to determine expected credit losses.

1 Accounting policies (continued)

Financial instruments (continued)

Fair value of financial instruments

Fair value amounts disclosed in these financial statements represent the company's estimate of the price at which a financial instrument could be exchange in an arm's length market transaction between knowledgeable, willing parties who are under no compulsion to act. They are point-in-time estimates that may change in subsequent reporting periods due to market conditions or other factors. Fair value is determined by reference to quoted prices in the most advantageous active market for that instrument to which the company has immediate access. However, where there is no active market for the company's financial instruments, the company determines fair value based on internal or external valuation models, such as stochastic models, option-pricing models and discounted cash flow models. These calculations represent management's best estimates based on a range of methods and assumptions. Since they are based on estimates the fair values may not be realised in an actual sale or immediate settlement of the instruments.

Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

Trade and other receivables

Trade receivables are amounts due from customers for merchandise sold or services performed in the ordinary course of business. If collection is expected in one year or less (or in the normal operating cycle of the business if longer), they are classified as current assets. If not, they are presented as non-current assets.

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment.

Cash and cash equivalents

In the cash flow statement cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet.

Trade and other payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

Trade and other payables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

Borrowings

Borrowings are recognised initially at fair value, net of direct issue costs and subsequently measured at amortised cost. Finance charges, including premiums payable on settlement or redemption and direct issue costs, are accounted for on an accruals basis to the income statement using the effective interest rate method and are added to the carrying amount of the instrument to the extent that they are not settled in the period in which they arise.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the balance sheet date.

1 Accounting policies (continued)

Current and deferred income tax

The tax expense for the year comprises current and deferred tax. Tax is recognised in the income statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case the tax is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the country where the company operates and generates taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred income tax is recognised, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates and laws that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. Deferred income tax is provided on temporary differences arising, except where the timing of the reversal of the temporary difference is controlled by the company and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.

Grants

Grants are recognised at their fair value where there is a reasonable assurance that the grant will be received and the company will comply with all attached conditions. Grants relating to costs are deferred and recognised in the income statement over the period necessary to match them with the costs that they are intended to compensate. Grants relating to property, plant and equipment are included in non-current liabilities as deferred income and are credited to the income statement on a straight-line basis over the expected useful economic lives of the related assets.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction, net of tax, from the proceeds.

Research and development

Expenditure on research is written off in the year in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset, as described above, are met.

1 Accounting policies (continued)

Research and development tax credits

Under UK tax legislation introduced in the 2013 Finance Bill research and development credits can be claimed against qualifying research and development expenditure. Where these credits are not expected to be restricted by the PAYE/NI cap included within the legislation then the credit is, in substance, a government grant. The company has elected to treat such credits as a government grant and recognise the credits in the same period as the research and development expenditure arises.

Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company's activities. Revenue is shown net of value-added tax.

The company is engaged in the provision of custom chemical synthesis services. The revenue for these services is recognised over time as the company has the right to receive payment as the services are provided.

The company is also involved in the supply of manufactured goods and the revenue within this stream is recognised at a point in time; being on delivery of the goods to the customer.

Foreign currency translation

Items included in the financial statements of each of the company's entities are measured using the currency of the primary economic environment in which the entity operates ("the functional currency"). The financial statements are presented in UK pound sterling, which is the company's functional and presentation currency.

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the income statement within 'finance income or cost'. All other foreign exchange gains and losses are presented in the income statement within administrative expenses.

Pension obligations

The company operates a defined contribution plan for employees whereby the company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. The company has no further payment obligations once the contributions have been paid. The contributions are recognised as an employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

1 Accounting policies (continued)

Leases

Definition

A lease is a contract, or a part of a contract, that conveys the right to use an asset or a physically distinct part of an asset ("the underlying asset") for a period of time in exchange for consideration. Further, the contract must convey the right to the Company to control the asset or a physically distinct portion thereof. A contract is deemed to convey the right to control the underlying asset if, throughout the period of use, the Company has the right to:

- Obtain substantially all the economic benefits from the use of the underlying asset, and;
- Direct the use of the underlying asset (e.g. direct how and for what purpose the asset is used)

Where contracts contain a lease coupled with an agreement to purchase or sell other goods or services (i.e., non-lease components), the non-lease components are identified and accounted for separately from the lease component. The consideration in the contract is allocated to the lease and non-lease components on a relative standalone price basis using the principles in IFRS 15.

The Almac Sciences (Scotland) Limited Company predominantly engages in leases for land and buildings, fixtures & fittings and computer equipment. The majority of leases for the Company are located in UK.

Initial recognition and measurement

The Company initially recognises a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term.

The lease liability is measured at the present value of the lease payments to be made over the lease term. The lease payments include fixed payments, purchase options at exercise price (where payment is reasonably certain), expected amount of residual value guarantees, termination option penalties (where payment is considered reasonably certain) and variable lease payments that depend on an index or rate.

The right-of-use asset is initially measured at the amount of the lease liability, adjusted for lease prepayments, lease incentives received, the Company's initial direct costs (e.g., commissions) and an estimate of restoration, removal and dismantling costs.

Subsequent measurement

After the commencement date, the Company measures the lease liability by

- (a) Increasing the carrying amount to reflect interest on the lease liability;
- (b) Reducing the carrying amount to reflect the lease payments made; and
- (c) Re-measuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in substance fixed lease payments or on the occurrence of other specific events.

Interest on the lease liability in each period during the lease term is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. Interest charges are included in finance cost in the income statement, unless the costs are included in the carrying amount of another asset applying other applicable standards. Variable lease payments not included in the measurement of the lease liability, are included in operating expenses in the period in which the event or condition that triggers them arises.

The related right-of-use asset is accounted for using the Cost model in IAS 16 and depreciated and charged in accordance with the depreciation requirements of IAS 16 Property, Plant and Equipment as disclosed in the accounting policy for Property, Plant and Equipment. Adjustments are made to the carrying value of the right of use asset where the lease liability is remeasured in accordance with the above. Right of use assets are tested for impairment in accordance with IAS 36 Impairment of assets as disclosed in the accounting policy in impairment.

1 Accounting policies (continued)

Leases (continued)

Lease modifications

If a lease is modified, the modified contract is evaluated to determine whether it is or contains a lease. If a lease continues to exist, the lease modification will result in either a separate lease or a change in the accounting for the existing lease.

The modification is accounted for as a separate lease if both:

- (a) The modification increases the scope of the lease by adding the right to use one or more underlying assets; and
- (b) The consideration for the lease increases by an amount commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the circumstances of the particular contract.

If both of these conditions are met, the lease modification results in two separate leases, the unmodified original lease and a separate lease. The Company then accounts for these in line with the accounting policy for new leases. If either of the conditions are not met, the modified lease is not accounted for as a separate lease and the consideration is allocated to the contract and the lease liability is re-measured using the lease term of the modified lease and the discount rate as determined at the effective date of the modification.

For a modification that fully or partially decreases the scope of the lease (e.g., reduces the square footage of leased space), IFRS 16 requires a lessee to decrease the carrying amount of the right-of-use asset to reflect partial or full termination of the lease. Any difference between those adjustments is recognised in profit or loss at the effective date of the modification.

For all other lease modifications which are not accounted for as a separate lease, IFRS 16 requires the lessee to recognise the amount of the re-measurement of the lease liability as an adjustment to the corresponding right-of-use asset without affecting profit or loss.

Short term leases

The Company has made an accounting policy election, by class of underlying asset, not to recognise lease assets and lease liabilities for leases with a lease term of 12 months or less (i.e., short-term leases).

Lease payments on short term leases are accounted for on a straight line bases over the term of the lease or other systematic basis if considered more appropriate. Short term lease payments are included in operating expenses in the income statement.

Sub leases

If an underlying asset is re-leased by the Company to a third party and the Company retains the primary obligation under the original lease, the transaction is deemed to be a sublease. The Company continues to account for the original lease (the head lease) as a lessee and accounts for the sublease as a lessor (intermediate lessor). When the head lease is a short term lease, the sublease is classified as an operating lease. Otherwise, the sublease is classified using the classification criteria applicable to Lessor Accounting in IFRS 16 by reference to the right-of-use asset in the head lease (and not the underlying asset of the head lease).

After classification lessor accounting is applied to the sublease.

1 Accounting policies (continued)

Share-based payments

The company issues cash-settled phantom share-based payments to certain employees of the company for their services to the company. The company accounts for these phantom share-based payments as cash-settled phantom share-based payments which are measured at fair value and recognised as an expense in the income statement with a corresponding increase in liabilities. The fair value is recognised over the period during which employees become unconditionally entitled to the awards, subject to the company's estimate of the number of awards which will lapse due to employees leaving the company prior to vesting. The total amount recognised in the income statement as an expense is adjusted to reflect the actual amount of awards that are expected to vest, except where forfeiture is due to an employee's termination of their contract.

2 Financial risk management

Financial risk factors

The company's operations expose it to a variety of financial risks that include the effects of changes in foreign exchange risk, credit risk and liquidity risk. The company has in place a risk management programme that seeks to limit the adverse effects on the financial performance of the company by monitoring the foregoing risks.

(a) Foreign exchange risk

While the greater part of the company's revenues and expenses are denominated in UK pound sterling, the company is exposed to foreign exchange risk in the normal course of business. While the company has not used financial instruments to date to hedge foreign exchange exposure, this position is kept constantly under review. If the US dollar had weakened/strengthened by 10% against the UK pound sterling spot rate on 30 September with all other variables held constant, the financial statements would have been impacted as follows:

		2021	•	2020 .
	Impact on post-tax profits	Impact on equity	Impact on post-tax losses.	Impact on equity
US dollar weakens by 10% against UK pound	(48,935)	(48,935)	(69,602)	(69,602)
US dollar strengthens by 10% against UK pound	59,810	59,810	85,069	. 85,069

(b) Interest rate risk

The company's interest rate risk arises mainly from amounts owed to group undertakings. Borrowings issued at variable rates expose the company to interest rate risk. Company policy is to maintain a mix of interest free advances and loans from group companies and variable interest rate borrowings from related parties. If interest rates had increased/decreased by 1% with all other variables held constant, the financial statements would have been impacted as follows:

•		2021		2020	
	Impact on post-tax profits	Impact on equity	Impact on post-tax profits £	Impact on equity £	
Interest rates increase by 1%	11,247	11,247	18,737	18,737	
Interest rates decrease by 1%	(11,247)	(11,247)	(18,737)	(18,737)	

2 Financial risk management (continued)

(c) Credit risk

The company has implemented policies that require appropriate credit checks on potential customers before sales are made. Credit control assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. The amount of exposure to individual customers is subject to limits, which are reassessed regularly. Credit risk also arises from cash and cash equivalents with banks and financial institutions. Banking arrangements are reviewed and regularly reassessed by the board.

(d) Liquidity risk

The company projects cash flow requirements as part of its annual budget setting process. Cash requirements are monitored dynamically by the company. As a result of its activities, the company is a net consumer of cash and combines related party funding with external sources to ensure that sufficient liquidity is maintained to allow continuous operation.

3 Capital risk management

The company is a subsidiary of Almac Group Limited, whose objectives when managing capital are to safeguard the group and company's ability to continue as a going concern in order to provide returns to shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. For further details, refer to the report and financial statements for Almac Group Limited.

4 Revenue

Revenue is attributable to the company's principal activities carried out in the United Kingdom

Timing of revenue is as follows:

	•						2021	2020
	•	•	•		:	۵	£	£.
Point in time				 			186,403	142,845
Over time		•				•	4,657,203	6,156,298
Total							4,843,606	6,299,143

5 Finance (costs)/income

		2021	2020
	•	£	£
Finance costs			
Interest payable on related party loans		(273)	(129)
Interest payable on IFRS 16 Leases		(58,451)	(62,027)
Finance costs ·	•	(58,724)	(62,156)
Finance income			
Interest receivable from group undertakings	. ,	25,590	50,100
Finance income		25,590	50,100
Finance (costs)/income - net		(33,134)	(12,056)

6 Expenses by nature

	 2021	2020
	£	£
Raw materials and consumables used	 881,556	984,986
Employee benefits expense (note 7)	1,596,181	1,392,609
Depreciation and amortisation	541,306	449,960
Depreciation on right of use assets	200,974	196,936
Transfer from capital grant reserve (note 17)	 (74,882)	(66,595)
Revenue grants		(227,000)
Other expenses*	864,985	709,825
Total cost of sales and administrative expenses	4,010,120	3,440,721

^{*}Other expenses of £864,985 (2020: £709,825) are stated after the deduction of £306,496 (2020: £287,594) of research and development tax credits.

Services provided by the auditors and network firms

During the year the company obtained the following services from the auditors at costs as detailed below:

		2021	2020
		£	£
Fees payable to the company's auditors for the audit of the financial statements		6,000	3,491
Fees payable to company's auditors for other services:	•		
- tax services		2,539	1,500
- other services		. •	950

7. Employees and directors

7 Employees and directors					2021	2020.
·	•				£	£
Staff costs during the year:						
Wages and salaries			• .		1,384,850	1,222,495
Social security costs		•	• • •		127,493	109,632
Other pension costs (note 20)				•	63,803	51,217
Share based payment costs (note 23)					20,035	9,265
				• • •	1,596,181	1,392,609

7 Employees and directors (continued)

•						2021		2020				
									Number			
Average monthly nu	mber of	persons e	mployed	(including d	irectors) during							
the year by activity:			•				. •					
Administration		•		·.			1		1			
Research			٠.				39		36			
	•	 -	•				40		37			

There were no key members of management during the year or the previous year other than the directors.

No directors (2020: nil) have retirement benefits accruing under a defined contribution plan nor were remunerated during the year (2020: £nil). Directors' remuneration is borne by other group companies. The directors do not believe it is practicable to apportion this amount between their services as directors of the company and their services as directors of fellow group undertakings. Directors' remuneration is disclosed for the group in Almac Group Limited financial statements (2020: None).

8 Income tax charge

• • •	2021	2020
	£	£
Current tax		
Current tax on profits for the year	(8,916)	(6,758)
Adjustment in respect of prior years	24	
Total current tax	(8,892)	(6,758)
Deferred tax		
Origination and reversal of timing differences	151,216	531,640
Adjustments in respect of prior periods	1,954	(16,362)
Effect of changes in tax rates	(89,266)	(103,058)
Total deferred tax	63,904	412,220
Income tax charge	55,012	405,462

The tax on the company's profit before tax differs from (2020: differs from) the theoretical amount that would arise using the weighted average tax rate applicable to profits of the company as follows:

	2021	· · · 2020
	£	£
Profit before income tax	800,352	. 2,846,366
Profit before income tax at the UK standard rate of 19% (2020: 19%)	152,067	540,810
Effects of:		
Expenses not deductible for tax purposes	22,372	13,000
Adjustment in respect of prior periods	1,978	(16,362)
Tax rate changes	(89,266)	(103,058)
Capital grants release not taxable	(18,362)	(12,653)
Transfer pricing adjustment	(13,777)	(16,275)
Income tax charge	55,012	.405,462
·······		

9 Intangible assets

			•	•			Computer software
			<u>·. </u>	•.		•	£
Cost At 1 October 2019							16,347
Additions							74,217
At 30 September 2020 and 1 O	ctober 2020			•	•		90,564
Additions							-
At 30 September 2021	; ·	•		•			90,564
		•					
Accumulated amortisation	•	**					
At 1 October 2019						٠.	11,804
Charge for the year		•			•	: .	9,333
At 30 September 2020 and 1 O	ctober 2020						21,137
Charge for the year	,	•		•	•		43,475
At 30 September 2021					•		64,612
						,	
Net book amount				•			
At 30 September 2021			•			•	25,952
At 30 September 2020		• •				-	69,427
At 30 September 2019			·	_			4,543

Amortisation is included within administrative expenses in the income statement.

10 Property, plant and equipment	Long leasehold land and buildings £	Plant and machinery	Fixtures, fittings and equipment £	Total £
Cost				
At 1 October 2019	207,961	5,002,010	123,259	5,333,230
Additions		835,599	52,483	888,082
At 30 September 2020 and 1 October 2020	207,961	.5,837,609	175,742	6,221,312
Additions		549,028	29,250	578,278
At 30 September 2021	207,961	6,386,637	204,992	6,799,590
Accumulated depreciation				
At 1 October 2019	207,961	1,991,665	82,994	2,282,620
Charge for the year		425,197	15,430	440,627
At 30 September 2020 and 1 October 2020	207,961	2,416,862	98,424	2,723,247
Charge for the year	- .	473,044	24,787	497,831
At 30 September 2021	207,961	2,889,906	123,211	3,221,078
Net book amount				
At 30 September 2021	•	3,496,731	81,781	3,578,512
At 30 September 2020	-	3,420,747	77,318	3,498,065
At 30 September 2019	-	3,010,345	40,265	3,050,610

Depreciation is included within administrative expenses in the income statement.

11 Right-of-use-assets

11 Mgni-ui-use-assets		Freehold land and buildings £	Fixtures, fittings and computer equipment £	Motor Vehicles £	Total £
Cost		· ·	:		
At 1 October 2019		-	• -	•	-
IFRS 16 adjustment		2,021,279	4,109	•	2,025,388
At 1 October 2020		2,021,279	. 4,109	·	2,025,388
Additions	•	-	-	22,736	22,736
At 30 September 2021		2,021,279	4,109	22,736	2,048,124
Accumulated depreciation					
At 1 October 2019 Charge for the year		195,771	1,165		196,936
At 01 October 2020	•	195,771	1,165	-	. 196,936
Charge for Year		199,707	803	464	200,974
At 30 September 2021		395,478	1,968	464	397,910
•					-
Net book value			•		
At 30 September 2021		1,625,801	2,141	22,272	1,650,214
At 30 September 2020		1,825,508	2,944		1,828,452
At 30 September 2019			·	_ ·	

The total cash outflow for leases in 2021 was £241,008 (2020: 229,833).

12 Deferred tax asset

The gross movement on the deferred income tax account is as follows:

The gross movement on the		6		2021	2020
•				£	£
At 1 October				455,210	846,959
Charged to the income sta	itement			(63,904)	(412,220)
Adjustment in respect to l	FRS 16 to equity	•	•	•	20,471
At 30 September			· · · · · · · · · · · · · · · · · · ·	391,306	455,210

The movement in deferred income tax assets and liabilities during the year, without taking into consideration the offsetting of balances within the same tax jurisdiction, is as follows:

	Tax losses	Accelerated capital allowances	Other temporary differences	R&D expenditure credit	Total
Deferred tax assets	£	£	£	£	£
At 1 October 2019	789,305	25,714	31,940	• •	846,959
(Charged)/credited to the income statement	(504,726)	91,370	(6,651)	7,7.87	(412,220)
Adjustment in respect to IFRS 16 to equity	• :	20,471		_	20,471
At 1 October 2020	284,579	137,555	25,289	7,787	455,210
(Charged)/credited to the income statement	(179,828)	113,359	. 2,587	(22)	(63,904)
At 30 September 2021	104,751	250,914	27,876	7,765	391,306
Deferred tax assets - to be received after more than 12 months				2021 £	2020 £ 455,210
			39	£	£
- to be received after more than 12 months			39	£ 1,306	£ 455,210
- to be received after more than 12 months Deferred tax assets			39	£ 1,306 1,306 2021	£ 455,210 455,210 2020
- to be received after more than 12 months Deferred tax assets Deferred tax assets recognised			39 39	£ 1,306 1,306 2021 £	£ 455,210 455,210 2020 £
- to be received after more than 12 months Deferred tax assets Deferred tax assets recognised Tax losses Accelerated capital allowances			39 39 10 25	£ 1,306 1,306 2021 £ 4,751	£ 455,210 455,210 2020 £ 284,579
- to be received after more than 12 months Deferred tax assets Deferred tax assets recognised Tax losses			39 39 10 25 2	£ 1,306 1,306 2021 £ 4,751 0,914	£ 455,210 455,210 2020 £ 284,579 137,555

13 Trade and other receivables

	2021	2020 -
	£	£
Trade receivables	942,353	803,312
Less: provision for impairment of trade receivables	· · · -	(13,362)
Trade receivables (net)	942,353	789,950
Amounts owed by group undertakings (note 24)	2,055,101	1,254,428
Group relief receivable (note 24)	315,411	294,374
Other receivables	26,325	965
Prepayments and accrued income	459,302	151,969
	3,798,492	2,491,686

The fair values of trade and other receivables are not materially different from the carrying values. For the purposes of IFRS 9 "Financial instruments" all of the company's trade and other receivables are classified as measured at amortised cost. Receivables are generally due for settlement within 30 days and are therefore all classified as current and are within credit terms.

Amounts owed by group undertakings are unsecured, interest free and repayable on demand.

The carrying amount of the company's trade and other receivables are denominated in the following currencies:

			•	2021	2020
	· .			£	£
Currency			 		
UK pound			•	3,144,552	1,911,674
US dollar	•	•		649,907	569,346
Euro				4,033	10,666
				3,798,492	2,491,686

The maximum exposure to credit risk at the reporting date is the fair value of each class of receivable above.

Trade receivables impaired and the amount of the impairment provision at 30 September 2021 was £Nil (2020: £13,362).

Movements on the provision for impairment of trade receivables are as follows:

	•			2021	2020
				£	£
At the beginning of the financial year		• ,		13,362	13,605
Exchange adjustment			•	-	(243)
Unused amounts reversed				(13,362)	<u>.</u>
At the end of the financial year		1	•		13,362

The creation and release of provision for impaired receivables have been included in administration expenses in the income statement.

13 Trade and other receivables (continued)

The company has recognised the following assets relating to contracts with customers (these are all included with accrued income):

•	2021	2020 £	
	£		
Contract assets recognised at start of the period	28,540	38,627	
Revenue recognised in prior periods that was invoiced in the current period	(28,540)	(38,627)	
Amounts recognised in revenue in the current period that will be invoiced i	n 309,318	28,540	
future periods			
Balance at the end of the period	309,318	28,540	

Contract assets are expected to be invoiced in the year to 30 September 2021

The company applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables and contract assets.

To measure the expected credit losses, trade receivables and contract assets have been grouped based on shared credit risk characteristics and the days past due. The contract assets relate to unbilled work in progress and have substantially the same risk characteristics as the trade receivables for the same types of contracts. The company has therefore concluded that the expected loss rates for trade receivables are a reasonable approximation of the loss rates for the contract assets.

The expected loss rates are based on the payment profiles of sales over a period of 12 months before 30 September and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables.

The company applies the practical expedient in IFRS 9 (which allows the company to measure impairment using the 12 month Expected Credit Loss model) in respect of amounts owed by group undertakings, for those balances that meet the following requirements:

- it has a low risk of default;
- the counterparty is considered, in the short term, to have a strong capacity to meet its obligations in the near term; and
- the company expects, in the longer term, that adverse changes in economic and business conditions might, but will not necessarily, reduce the ability of the counterparty to fulfil its obligations.

For those balances where there is a higher risk of default the company follows the 3-stage approach within IFRS 9 to determine lifetime expected credit losses.

Notes to the financial statements for the year ended 30 September 2021 (continued)

14 Borrowings

	2021	2020
Current	£	£
Amounts owed to group undertakings (notes 15 and 24)	3,349,719	3,349,719
Lease liabilities arising from IFRS 16	206,542	180,383
	3,556,261	3,530,102
Non-current	2021 £	2020 £
Lease liabilities arising from IFRS 16	1,589,617	1,775,598
Total borrowings	5,145,878	5,305,700

Amounts owed to group undertakings are unsecured, interest free and have no set date of repayment.

The fair value of current and non-current borrowings equals their carrying amount as the impact of discounting is not significant. The fair values are based on cash flows discounted using a rate based on the borrowing rate of 4%.

For the purposes of IFRS 9 "Financial instruments" the financial liabilities noted above are classified as measured at amortised cost.

Maturity of financial liabilities

The effective interest rates at the balance sheet date were as follows:

•					2021	- 2020
		• .	*		%	%
Borrowings	<u> </u>				2.18%	2.66

The maturity profile of the carrying amount of non-current borrowings at 30 September was as follows:

		Lease liabilities £	Total 2021 £
In more than 1 year but not more than 2 years	· ·	211,590	211,590
In more than 2 years but not more than 5 years		666,229	666,229
In more than 5 years		711,798	711,798
		1,589,617	1,589,617
		Lease liabilities £	Total 2020 £
In more than 1 year but not more than 2 years		251,866	251,866
In more than 2 years but not more than 5 years		754,457	754,457
In more than 5 years		995,507	995,507
	•	-2 001 830	2 001 830

14 Borrowings (continued)

The amounts included in the tables below are the contractual undiscounted cash flows of current and non-current borrowings.

		Lease liabilities £	Total 2021 £
Less than 1	•	251,869	251,869
In more than 1 year but not more than 2 years		251,866	251,866
In more than 2 years but not more than 5 years		753,600	753,600
In more than 5 years		744,498	744,498
	·	2,001,833	2,001,833
		Lease liabilities £	Total 2020 £
Less than 1		241,034	241,034
In more than 1 year but not more than 2 years		251,866	251,866
In more than 2 years but not more than 5 years		754,457	754,457
In more than 5 years		995,507	995,507
		2,242,864	2,242,864
15 Trade and other payables			
		2021	2020
	•	£	£
Trade payables		130,713	105,519
Amounts owed to group undertakings (note 14 & 24)		230,033	225,226
Other tax and social security		31,354	32,932
Other creditors		12,759	13,652
Accruals and deferred income		459,048	319,017
	•	863,907	696,346

The fair value of trade and other payables are not materially different from their carrying value as the impact of discounting is not significant. There is no difference between the amounts shown above and the total contractual undiscounted cash flows of trade and other payables. For the purposes of IFRS 9 "Financial instruments" the financial liabilities noted above are classified as measured at amortised cost.

Amounts owed to group undertakings are unsecured, interest free and repayable on demand.

The company has recognised the following liabilities relating to contracts with customers (these are all included with deferred income):

	2021	2020
	£	£
Contract liabilities recognised at start of the period	(32,439)	(45,841)
Amounts invoiced in prior periods recognised as revenue in the current period	32,439	45,841
Amounts invoiced in the current period which will be recognised as revenue in later		
periods	(173,785)	(32,439)
Balance at the end of the period	(173,785)	(32,439)

Contract liabilities are expected to be recognised as revenue within 12 months of the period end.

16 Other non-current liabilities

				2021	2020
		• •		£	£
Accruals and deferre	d income		· · · · · ·	87,790	97,617

Maturity of other non-current liabilities

The maturity profile of the carrying amount of other non-current liabilities at 30 September was as follows:

		;	2021	2020
	• . •		£	£
In more than one year but not more than two years			39,747	33,458
In more than two years but not more than five years			36,204	53,579
More than five year	•		11,839	10,580
		•	87,790	97,617

There is no difference between the amounts shown above and the total contractual undiscounted cash flows of other non-current liabilities.

17 Deferred income

Government grants			•		£
At 1 October 2019			· ·		530,386
Released to the income statement	•	•		•	(66,595)
At 30 September 2020 and 1 October 2020					463,791
Grants received					433,266
Released to the income statement		•		·	(74,882)
At 30 September 2021		: .			822,175
18 Share capital				2021	2020
		·	·.	£	£
Allotted and fully paid					
20,720,500 (2020: 20,720,500) ordinary shares	of £0.05 (20	020: £0.05)	each	1,036,025	1,036,025

19 Cash generated from operations

Cash ge	nerated j	from e	operations (
---------	-----------	--------	--------------

	2021	2020
	£	£
Profit before income tax	800,352	2,846,366
Adjustments for:		
Depreciation of property, plant and equipment	497,831	440,627
Depreciation of right of use assets	200,974	196,936
Amortisation of intangible assets	43,475	9,333
Release of capital grant	(74,882)	(66,595)
Finance income	(25,590)	(50,100)
Finance cost	58,724	62,156
Movement in trade and other receivables	(791,592)	(538,110)
Movement in trade and other payables	157,734	(2,162,693)
Net cash generated from operations	867,026	737,920

Net debt as at 30 September 2021

	Related parties £	Leases	Subtotal £	Cash £	Total £
Net debt as at 1 October 2019	(1,401,124)		(1,401,124)		(1,401,124)
Recognised on adoption of IFRS 16	=	(1,652,715)	(1,652,715)	-	(1,652,715)
Cash flows	146,696	229,833	376,529	-	376,529
Acquisitions - leases	-	(471,072)	(471,072)	· . -	(471,072)
Other changes	-	(62,027)	(62,027)	-	(62,027)
Net debt as at 30 September 2020	(1,254,428)	(1,955,981)	(3,210,409)		(3,210,409)
Cash flows	(800,673)	241,008	(559,665)		(559,665)
Acquisitions - leases	· -	(22,736)	(22,736)	-	(22,736)
Other changes	-	(58,451)	(58,451)	-	(58,451)
Net debt as at 30 September 2021	(2,055,101)	(1,796,160)	(3,851,261)	-	(3,851,261)

20 Pension commitments

The company participates in a group defined contribution scheme for employees whereby the assets of the scheme are held separately from those of the group in an independently administered scheme. Contributions are charged to the income statement in the year to which they relate.

Pension costs for the defined contribution scheme are as follows:

			•			2021	2020
		,	, .		•	£	· £
Defined contribution scheme	. :			 		63,803	51,217

Amounts owed to the pension scheme as at 30 September 2021 totalled £11,775 (2020: £11,294).

21 Capital and other financial commitments

	2021	2020
	£	£
Contracts placed for future property, plant and equipment expenditure not provided		
in the financial statements	56,808	117,228

22 Contingent liabilities

There exists a contingent liability to repay certain capital and revenue grants received from Invest Northern Ireland (formerly the Industrial Development Board) if future employment levels fall below specified levels. The directors do not anticipate any repayment falling due under the terms on which the grants were received.

The company is party to an unlimited intercompany cross guarantee in relation to group banking facilities in the United Kingdom.

23 Share based payments

The company operates a phantom share scheme whereby share awards are granted to directors and senior management employees. The share award is granted for £nil consideration, and is conditional on the director or employee continuing in employment for a period of three years from the date the share award is made, which is the first of January following the financial year end. The company accounts for these share awards as cash-settled share-based payments which are measured at fair value and recognised as an expense in the income statement with a corresponding increase in liabilities. The fair value is recognised over the period during which employees become unconditionally entitled to the awards, subject to the company's estimate of the number of awards which will lapse due to employees leaving the company prior to vesting. The total amount recognised in the income statement as an expense is adjusted to reflect the actual amount of awards that are expected to vest, except where forfeiture is due to employee's termination of contract.

Share awards are exercisable from 1 January, three years, following the award date. The share award is exercisable at the share price the end of financial year when the share is exercisable, and all share awards are cash settled.

The fair value of each share award granted and the assumptions used in the calculation are as follows:

Grant date				2021	2020
Share price at grant date	e · .		•	£1.300	£1.023
Number of employees				1	. 1
Share awards		•	•	5,223	6,396
Vesting period (years)				4* ,	4*
Option life (years)				4	4
Expected life (years)		• :		. 4	4
Fair value				£1.300	£1.023

^{*}The vesting period is four years which is made up of the three years from the date of issue plus the year of service incurred in order to be eligible for the award.

The fair value of share awards granted during the year was £1.300 (2020: £1.023). The significant inputs into the model were the share price at grant date, exercise price, dividend yield, risk free interest rate and expected option life as shown above.

23 Share based payments (continued)

Movements in the number of share awards outstanding are as follows:

				2021	2020	
	•			Number	Number	
Outstanding at the beginning of the financial year			 	20,201	21,702	
Granted		•		5,223	6,396	
Exercised				(6,785)	(7,897)	
Outstanding at the end of the financial year			•	18,639	20,201	
Exercisable on 1 January 2022/2021				7,020	6,785	

The weighted average share price of share awards exercised in the year was £1.300 (2020: £1.023).

Share awards outstanding at the end of the year have the following expiry dates:

	•		• .			٠.	2021	2020
							Number	Number
2021	-		٠,			·	·	6,785
2022	• •						7,020	7,020
2023		•					6,396	6,396
2024				• • •	•		5,223	
•		•				*****	18,639	20,201

The total expense recognised in the income statement was £20,035 (2020: £9,265). The year-end liability is £17,652 (2020: £24,598).

24 Ultimate controlling party and related party transactions

The ultimate parent undertaking and the largest and smallest group of undertakings of which the company is a member and for which group financial statements are prepared is Almac Group Limited, a company incorporated in Northern Ireland. The registered office of Almac Group Limited is Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD. Copies of the group financial statements are available from Companies Registry.

At the balance sheet date, the ultimate controlling parties are A D Armstrong, S Campbell, J Irvine, and C Hayburn.

The McClay Foundation is a related party due to common directors.

Companies within Almac Group Limited are related parties of Almac Sciences (Scotland) Limited.

Transactions entered into during the year and year end balances with companies within Almac Group Limited were as follows:

Transactions	2021	. 2020
	£	£
Sales to group undertakings	712,053	513,466
Purchases from group undertakings	(11,631)	. (90,069)
Management charge paid	(228,838)	(224,222)
Interest received from group undertakings	25,590	50,100
Interest paid to group undertakings	(273)	(129)
Balances	2021	2020
	£	. £ .
Amounts owed to group undertakings	(3,579,752)	(3,574,945)
Amounts owed by group undertakings	2,055,101	1,254,428
Group relief receivable	315,411	294,374

Details of amounts owed by and to group undertakings are disclosed in notes 13, 14 and 15 respectively. Details of interest payable and receivable on balances held with group undertakings are disclosed in note 5.